Corvus Pharmaceuticals Net Worth
Corvus Pharmaceuticals Net Worth Breakdown | CRVS |
Corvus Pharmaceuticals Net Worth Analysis
Corvus Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Corvus Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Corvus Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Corvus Pharmaceuticals' net worth analysis. One common approach is to calculate Corvus Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Corvus Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Corvus Pharmaceuticals' net worth. This approach calculates the present value of Corvus Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Corvus Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Corvus Pharmaceuticals' net worth. This involves comparing Corvus Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Corvus Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Corvus Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Corvus Pharmaceuticals' net worth research are outlined below:
| Corvus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Corvus Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (27.03 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Corvus Pharmaceuticals currently holds about 56.72 M in cash with (23.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. | |
| Corvus Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
Corvus Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Corvus Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Corvus Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Corvus Pharmaceuticals Target Price Consensus
Corvus target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Corvus Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most Corvus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Corvus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Corvus Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCorvus Pharmaceuticals Target Price Projection
Corvus Pharmaceuticals' current and average target prices are 4.88 and 14.80, respectively. The current price of Corvus Pharmaceuticals is the price at which Corvus Pharmaceuticals is currently trading. On the other hand, Corvus Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Corvus Pharmaceuticals Market Quote on 17th of February 2025
Target Price
Analyst Consensus On Corvus Pharmaceuticals Target Price
Know Corvus Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Corvus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Corvus Pharmaceuticals backward and forwards among themselves. Corvus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Corvus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-09-30 | 376.1 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 331.4 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 323.2 K | Millennium Management Llc | 2024-09-30 | 311.3 K | Susquehanna International Group, Llp | 2024-09-30 | 219 K | State Street Corp | 2024-09-30 | 178.2 K | Qube Research & Technologies | 2024-09-30 | 127.3 K | Bridgeway Capital Management, Llc | 2024-09-30 | 127.3 K | Citigroup Inc | 2024-09-30 | 122.9 K | Orbimed Advisors, Llc | 2024-09-30 | 6.9 M | Point72 Asset Management, L.p. | 2024-09-30 | 5.6 M |
Follow Corvus Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 313.58 M.Market Cap |
|
Project Corvus Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.68) | (0.72) | |
| Return On Capital Employed | (0.70) | (0.73) | |
| Return On Assets | (0.68) | (0.72) | |
| Return On Equity | (0.80) | (0.76) |
When accessing Corvus Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Corvus Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Corvus Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Corvus Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Corvus Pharmaceuticals. Check Corvus Pharmaceuticals' Beneish M Score to see the likelihood of Corvus Pharmaceuticals' management manipulating its earnings.
Evaluate Corvus Pharmaceuticals' management efficiency
Corvus Pharmaceuticals has return on total asset (ROA) of (0.283) % which means that it has lost $0.283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0048) %, meaning that it created substantial loss on money invested by shareholders. Corvus Pharmaceuticals' management efficiency ratios could be used to measure how well Corvus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.72 in 2025. Return On Capital Employed is likely to drop to -0.73 in 2025. At this time, Corvus Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 72.5 M in 2025, whereas Other Current Assets are likely to drop slightly above 687.3 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.93 | 0.88 | |
| Tangible Book Value Per Share | 0.93 | 0.88 | |
| Enterprise Value Over EBITDA | (2.45) | (2.58) | |
| Price Book Value Ratio | 1.97 | 2.06 | |
| Enterprise Value Multiple | (2.45) | (2.58) | |
| Price Fair Value | 1.97 | 2.06 | |
| Enterprise Value | 84.3 M | 80.6 M |
The leadership approach at Corvus Pharmaceuticals' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Corvus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Corvus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Corvus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Corvus Pharmaceuticals Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 23rd of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 1st of August 2024 An amended filing to the original Schedule 13G | ViewVerify |
Corvus Pharmaceuticals Earnings Estimation Breakdown
The calculation of Corvus Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Corvus Pharmaceuticals is estimated to be -0.2305 with the future projection ranging from a low of -0.2375 to a high of -0.225. Please be aware that this consensus of annual earnings estimates for Corvus Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.24 Lowest | Expected EPS | -0.23 Highest |
Corvus Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Corvus Pharmaceuticals' value are higher than the current market price of the Corvus Pharmaceuticals stock. In this case, investors may conclude that Corvus Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Corvus Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 6 | 65.53% | -0.6 | -0.2305 | -0.99 |
Corvus Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Corvus Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Corvus Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Corvus Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Corvus Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Corvus Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Corvus Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Corvus Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Corvus Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-05 | 2024-09-30 | -0.11 | -0.6 | -0.49 | 445 | ||
2024-08-06 | 2024-06-30 | -0.11 | -0.04 | 0.07 | 63 | ||
2024-05-06 | 2024-03-31 | -0.13 | -0.12 | 0.01 | 7 | ||
2024-03-19 | 2023-12-31 | -0.12 | -0.14 | -0.02 | 16 | ||
2023-11-07 | 2023-09-30 | -0.12 | -0.12 | 0.0 | 0 | ||
2023-08-08 | 2023-06-30 | -0.14 | -0.14 | 0.0 | 0 | ||
2023-05-08 | 2023-03-31 | -0.16 | -0.17 | -0.01 | 6 | ||
2023-03-28 | 2022-12-31 | -0.23 | -0.21 | 0.02 | 8 | ||
2022-11-03 | 2022-09-30 | -0.16 | -0.32 | -0.16 | 100 | ||
2022-08-08 | 2022-06-30 | -0.18 | -0.18 | 0.0 | 0 | ||
2022-05-05 | 2022-03-31 | -0.15 | -0.18 | -0.03 | 20 | ||
2022-03-10 | 2021-12-31 | -0.19 | -0.2 | -0.01 | 5 | ||
2021-11-01 | 2021-09-30 | -0.26 | -0.24 | 0.02 | 7 | ||
2021-08-02 | 2021-06-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2021-04-29 | 2021-03-31 | -0.31 | -0.34 | -0.03 | 9 | ||
2021-03-25 | 2020-12-31 | -0.32 | -0.33 | -0.01 | 3 | ||
2020-10-29 | 2020-09-30 | -0.24 | -0.33 | -0.09 | 37 | ||
2020-07-30 | 2020-06-30 | -0.28 | -0.36 | -0.08 | 28 | ||
2020-04-30 | 2020-03-31 | -0.4 | -0.44 | -0.04 | 10 | ||
2020-03-05 | 2019-12-31 | -0.33 | -0.38 | -0.05 | 15 | ||
2019-10-29 | 2019-09-30 | -0.41 | -0.37 | 0.04 | 9 | ||
2019-08-01 | 2019-06-30 | -0.43 | -0.44 | -0.01 | 2 | ||
2019-05-09 | 2019-03-31 | -0.4 | -0.4 | 0.0 | 0 | ||
2019-03-07 | 2018-12-31 | -0.46 | -0.36 | 0.1 | 21 | ||
2018-11-01 | 2018-09-30 | -0.48 | -0.36 | 0.12 | 25 | ||
2018-08-02 | 2018-06-30 | -0.59 | -0.4 | 0.19 | 32 | ||
2018-05-03 | 2018-03-31 | -0.74 | -0.63 | 0.11 | 14 | ||
2018-03-01 | 2017-12-31 | -0.77 | -0.58 | 0.19 | 24 | ||
2017-11-02 | 2017-09-30 | -0.81 | -0.62 | 0.19 | 23 | ||
2017-08-03 | 2017-06-30 | -0.74 | -0.73 | 0.01 | 1 | ||
2017-05-04 | 2017-03-31 | -0.77 | -0.79 | -0.02 | 2 | ||
2017-03-10 | 2016-12-31 | -0.57 | -0.55 | 0.02 | 3 | ||
2016-11-03 | 2016-09-30 | -0.45 | -0.51 | -0.06 | 13 | ||
2016-08-04 | 2016-06-30 | -0.36 | -0.43 | -0.07 | 19 | ||
2016-05-05 | 2016-03-31 | -1.91 | -5.39 | -3.48 | 182 |
Corvus Pharmaceuticals Corporate Management
| Leiv Lea | Chief Officer | Profile | |
| James MD | Senior Research | Profile | |
| Alan Esq | Sec | Profile | |
| MD FACP | CoFounder Director | Profile | |
| Jeffrey Arcara | Chief Officer | Profile |
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.